Pr MD - Erytech Pharma Consultant Board
Insider
Pr MD is Consultant Board of Erytech Pharma SA
| Phone | 33 4 78 74 44 38 |
| Web | https://www.erytech.com |
Erytech Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3014) % which means that it has lost $0.3014 on every $100 spent on assets. This is way below average. Erytech Pharma's management efficiency ratios could be used to measure how well Erytech Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Erytech Pharma SA currently holds 13.57 M in liabilities with Debt to Equity (D/E) ratio of 1.0, which is about average as compared to similar companies. Erytech Pharma SA has a current ratio of 2.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Erytech Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Alexandra MD | Avenue Therapeutics | 58 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| MPA MD | Unicycive Therapeutics | 52 | |
| Charles Williams | Surrozen | 45 | |
| Timothy Dyer | Addex Therapeutics | 57 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Patrick Amstutz | Molecular Partners AG | 50 | |
| Elizabeth Nguyen | Surrozen | N/A | |
| Duane BA | Armata Pharmaceuticals | 74 | |
| MBA MD | Ikena Oncology | 59 | |
| Clark Cheng | Aptorum Group Ltd | 44 | |
| David MacDonald | XORTX Therapeutics | 61 | |
| Todd MBA | Armata Pharmaceuticals | 61 | |
| MRCP MD | XORTX Therapeutics | 75 | |
| Hing Wong | HCW Biologics | 70 | |
| Bart Anderson | Exicure | N/A | |
| MS JD | Surrozen | 62 | |
| Sarah Longoria | Exicure | 42 | |
| Pascal Caisey | Genfit | 56 | |
| Alexander Zurcher | Molecular Partners AG | 50 | |
| Nick Rigopoulos | XORTX Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 |
Erytech Pharma SA Leadership Team
Elected by the shareholders, the Erytech Pharma's board of directors comprises two types of representatives: Erytech Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Erytech. The board's role is to monitor Erytech Pharma's management team and ensure that shareholders' interests are well served. Erytech Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Erytech Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gil BVBA, CEO Director | ||
| Iman MD, Chief Officer | ||
| Philip Lorenzi, Consultant Board | ||
| AnneCcile Fumey, HR Director | ||
| Brian Schwab, Chief Counsel | ||
| Naomi Eichenbaum, Director Relations | ||
| Eric Soyer, CFO, COO | ||
| Bridget Bax, Consultant Board | ||
| Jrme PharmD, Chief Operations | ||
| Pr MD, Consultant Board |
Erytech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Erytech Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (4.08) % | |||
| Current Valuation | 211.16 K | |||
| Shares Outstanding | 34.12 M | |||
| Shares Owned By Institutions | 7.65 % | |||
| Number Of Shares Shorted | 17.79 K | |||
| Price To Earning | (5.88) X | |||
| Price To Book | 0.65 X |
Pair Trading with Erytech Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Erytech Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Erytech Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |